Influence of Lysosomal Sequestration on Multidrug Resistance in Cancer Cells

Overview

Journal Cancer Drug Resist

Date 2022 May 18

PMID 35582144

Authors

Reginald Halaby

Affiliations

Soon will be listed here.

Abstract

Chemotherapy remains a primary treatment modality for various malignancies. However, resistance to chemotherapeutic drugs is a major obstacle to curative cancer therapy. Lysosomes are acidic organelles that participate in cellular digestion. However, there is rising interest in lysosomes because of their involvement with cancer. For example, extracellular secretion of lysosomal enzymes promote tumorigenesis; cytosolic leakage of lysosomal hydrolases promote apoptosis; and weak chemotherapeutic bases diffuse across the lysosomal membrane and become entrapped in lysosomes in their cationic state. Lysosomal drug sequestration lowers the cytotoxic potential of chemotherapeutics, reduces drug availability to sites of action, and contributes to cancer resistance. This review examines various mechanisms of lysosomal drug sequestration and their consequences on cancer multidrug resistance. Strategies for overcoming drug resistance by exploiting lysosomes as subcellular targets to reverse drug sequestration and drug resistance are also discussed.

Citing Articles

A protracted war against cancer drug resistance.

Tian Y, Wang X, Wu C, Qiao J, Jin H, Li H Cancer Cell Int. 2024; 24(1):326.

PMID: 39342202 PMC: 11439304. DOI: 10.1186/s12935-024-03510-2.

Unraveling the role of long non-coding RNAs in therapeutic resistance in acute myeloid leukemia: New prospects & challenges.

Sharma S Noncoding RNA Res. 2024; 9(4):1203-1221.

PMID: 39036603 PMC: 11259994. DOI: 10.1016/j.ncrna.2024.05.009.

Impact of Obesity and Lysosomal Dysfunction on Chemoresistance in Ovarian Cancer.

Kim B, Jung J Biomedicines. 2024; 12(3).

PMID: 38540217 PMC: 10967917. DOI: 10.3390/biomedicines12030604.

Targeting Lysosomes: A Strategy Against Chemoresistance in Cancer.

Shirbhate E, Singh V, Mishra A, Jahoriya V, Veerasamy R, Tiwari A Mini Rev Med Chem. 2024; 24(15):1449-1468.

PMID: 38343053 DOI: 10.2174/0113895575287242240129120002.

Modulation of Cisplatin Sensitivity through TRPML1-Mediated Lysosomal Exocytosis in Ovarian Cancer Cells: A Comprehensive Metabolomic Approach.

Kim B, Kim G, Kim H, Song Y, Jung J Cells. 2024; 13(2).

PMID: 38247807 PMC: 10814698. DOI: 10.3390/cells13020115.

References

Basha Syed S, Arya H, Fu I, Yeh T, Periyasamy L, Hsieh H . Targeting P-glycoprotein: Investigation of piperine analogs for overcoming drug resistance in cancer. Sci Rep. 2017; 7(1):7972. PMC: 5554262. DOI: 10.1038/s41598-017-08062-2. View

Kon S, Kobayashi N, Satake M . Altered trafficking of mutated growth factor receptors and their associated molecules: implication for human cancers. Cell Logist. 2014; 4:e28461. PMC: 4156482. DOI: 10.4161/cl.28461. View

Higgins C . Multiple molecular mechanisms for multidrug resistance transporters. Nature. 2007; 446(7137):749-57. DOI: 10.1038/nature05630. View

Holohan C, Van Schaeybroeck S, Longley D, Johnston P . Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013; 13(10):714-26. DOI: 10.1038/nrc3599. View

Guillaumot P, Luquain C, Malek M, Huber A, Brugiere S, Garin J . Pdro, a protein associated with late endosomes and lysosomes and implicated in cellular cholesterol homeostasis. PLoS One. 2010; 5(6):e10977. PMC: 2882324. DOI: 10.1371/journal.pone.0010977. View

Gotink K, Broxterman H, Honeywell R, Dekker H, de Haas R, Miles K . Acquired tumor cell resistance to sunitinib causes resistance in a HT-29 human colon cancer xenograft mouse model without affecting sunitinib biodistribution or the tumor microvasculature. Oncoscience. 2015; 1(12):844-53. PMC: 4303892. DOI: 10.18632/oncoscience.106. View

Salvador N, Aguado C, Horst M, Knecht E . Import of a cytosolic protein into lysosomes by chaperone-mediated autophagy depends on its folding state. J Biol Chem. 2000; 275(35):27447-56. DOI: 10.1074/jbc.M001394200. View

Jansson P, Yamagishi T, Arvind A, Seebacher N, Gutierrez E, Stacy A . Di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT) overcomes multidrug resistance by a novel mechanism involving the hijacking of lysosomal P-glycoprotein (Pgp). J Biol Chem. 2015; 290(15):9588-603. PMC: 4392262. DOI: 10.1074/jbc.M114.631283. View

Kunjachan S, Rychlik B, Storm G, Kiessling F, Lammers T . Multidrug resistance: Physiological principles and nanomedical solutions. Adv Drug Deliv Rev. 2013; 65(13-14):1852-1865. PMC: 3939439. DOI: 10.1016/j.addr.2013.09.018. View

10.

Hurwitz S, Terashima M, Mizunuma N, Slapak C . Vesicular anthracycline accumulation in doxorubicin-selected U-937 cells: participation of lysosomes. Blood. 1997; 89(10):3745-54. View

11.

Hahne J, Kurz A, Meyer S, Dietl J, Engel J, Honig A . Anti-tumour activity of phosphoinositide-3-kinase antagonist AEZS-126 in models of ovarian cancer. Arch Gynecol Obstet. 2014; 291(1):131-41. DOI: 10.1007/s00404-014-3389-z. View

12.

Rajagopal A, Simon S . Subcellular localization and activity of multidrug resistance proteins. Mol Biol Cell. 2003; 14(8):3389-99. PMC: 181575. DOI: 10.1091/mbc.e02-11-0704. View

13.

Gotink K, Broxterman H, Labots M, de Haas R, Dekker H, Honeywell R . Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. Clin Cancer Res. 2011; 17(23):7337-46. PMC: 4461037. DOI: 10.1158/1078-0432.CCR-11-1667. View

14.

Guan J, Zhang X, Sun W, Qi L, Wu J, Qin Z . DRAM1 regulates apoptosis through increasing protein levels and lysosomal localization of BAX. Cell Death Dis. 2015; 6:e1624. PMC: 4669745. DOI: 10.1038/cddis.2014.546. View

15.

Wang E, Lee M, Dunn K . Lysosomal accumulation of drugs in drug-sensitive MES-SA but not multidrug-resistant MES-SA/Dx5 uterine sarcoma cells. J Cell Physiol. 2000; 184(2):263-74. DOI: 10.1002/1097-4652(200008)184:2<263::AID-JCP15>3.0.CO;2-F. View

16.

Englinger B, Kallus S, Senkiv J, Heilos D, Gabler L, van Schoonhoven S . Intrinsic fluorescence of the clinically approved multikinase inhibitor nintedanib reveals lysosomal sequestration as resistance mechanism in FGFR-driven lung cancer. J Exp Clin Cancer Res. 2017; 36(1):122. PMC: 5590147. DOI: 10.1186/s13046-017-0592-3. View

17.

Sardiello M, Palmieri M, di Ronza A, Medina D, Valenza M, Gennarino V . A gene network regulating lysosomal biogenesis and function. Science. 2009; 325(5939):473-7. DOI: 10.1126/science.1174447. View

18.

Forgac M . Vacuolar ATPases: rotary proton pumps in physiology and pathophysiology. Nat Rev Mol Cell Biol. 2007; 8(11):917-29. DOI: 10.1038/nrm2272. View

19.

Cuvier C, Millot J, Lizard G, Chevillard S, Manfait M, Couvreur P . Doxorubicin-loaded nanospheres bypass tumor cell multidrug resistance. Biochem Pharmacol. 1992; 44(3):509-17. DOI: 10.1016/0006-2952(92)90443-m. View

20.

Palermo C, Joyce J . Cysteine cathepsin proteases as pharmacological targets in cancer. Trends Pharmacol Sci. 2007; 29(1):22-8. DOI: 10.1016/j.tips.2007.10.011. View